Ignite Creation Date:
2025-12-25 @ 12:39 AM
Ignite Modification Date:
2026-01-01 @ 7:22 PM
Study NCT ID:
NCT07085767
Status:
RECRUITING
Last Update Posted:
2025-12-02
First Post:
2025-07-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Sponsor:
Olema Pharmaceuticals, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-11-03
Start Date Type:
ACTUAL
Primary Completion Date:
2028-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2032-01
Completion Date Type:
ESTIMATED
First Submit Date:
2025-07-08
First Submit QC Date:
None
Study First Post Date:
2025-07-25
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-24
Last Update Post Date:
2025-12-02
Last Update Post Date Type:
ESTIMATED